The ChAdOx1 vaccine is currently being tested by the British pharmaceutical corporation AstraZeneca in collaboration with the University of Oxford and the Italian center Irbm of Pomezia.
The ChAdOx1 vaccine against the SARS-CoV-2 coronavirus, developed by scientists at the Jenner Institute at Oxford University and tested in collaboration with the British pharmaceutical multinational AstraZeneca and the Italian research center Irbm of Pomezia, may go on sale as early as January 2021. This was announced by the President of Irbm of Pomezia Piero Di Lorenzo in an interview with the newspaper Libero.
ChAdOx1 is based on a chimpanzee adenovirus containing the full-length structural surface glycoprotein (S-protein) SARS-CoV-2 with a plasminogen activator leader sequence. Now it is in the third stage of clinical tests, in which about 10 thousand people participate. The studies are scheduled for completion in September and will also involve 30,000 people in the United States, 2,000 South Africans, and 5,000 Brazilians. As noted by Di Lorenzo, first they organize vaccinations for people who are at the highest risk of contracting coronavirus.
According to preliminary agreements, ChAdOx1 will first appear in Italy and the UK, then in the Netherlands, France, and Germany. The United Kingdom has already ordered about 100 million doses of the vaccine, according to the BBC. At the same time, the head of the Irbm of Pomezia is confident that vaccination will proceed at a rapid pace, so that within 12 months “the planet will be protected.” The commercial price of the drug will be around two to three euros.
According to a report published in The Lancet on the results of one of the testing stages, from April 23 to May 21, 543 volunteers aged 18 to 55 years were injected with ChAdOx1 as a single injection into the deltoid muscle (another 534 people received MenACWY, used as a vaccine) comparator). “There were no serious side effects associated with ChAdOx1. Spike-specific T cell responses peaked on day 14. The level of IgG antibodies against SARS-CoV-2 increased by the 28th day and increased after the second dose. After the booster dose, all subjects showed neutralizing activity, “the report says.
Thus, the scientists write, the ChAdOx1 vaccine showed “an acceptable safety profile, and homologous enhancement helped generate a large number of antibodies.” “These results, together with the induction of both humoral and cellular immune responses, support a large-scale evaluation of this candidate vaccine in ongoing tests,” the authors of the report added.